Category: progress
-
Argenx stock gets H.C. Wainwright nod on Vyvgart growth and pipeline progress By Investing.com
•
On Friday, HC Wainwright reaffirmed a Buy rating on biopharmaceutical company argenx SE (NASDAQ: ARGX), with a firm price target of $448.00. The Company’s confidence in argenx is rooted in the Company’s successful introduction of Vyvgart for the treatment of myasthenia gravis (MG), which has been recognized as one of…
-
Gritstone bio details progress in cancer vaccine trials By Investing.com
•
Gritstone bio (GRTS) has unveiled promising preliminary data from its GRANITE personalized cancer vaccine program during its First Quarter 2024 Earnings Call. The clinical updates showed a positive trend in progression-free survival (PFS) for colorectal cancer patients, with particularly encouraging results in high-risk individuals. The company’s financial position was also…
-
Exelon reports steady progress and regulatory wins By Investing.com
•
Exelon Corporation (NASDAQ:) has reported its first quarter earnings, indicating a solid performance with earnings of $0.66 per share on a GAAP basis and $0.68 per share on a non-GAAP basis. The energy giant is on track to meet its annual financial expectations and has made significant strides on the…
-
FOMC Holds Rates Steady, Reiterates ‘Lack of Progress’ on Inflation
•
As expected, the Federal Open Market Committee (FOMC) kept interest rates unchanged at 5.25-5.50% during its May meeting. However, US central bank officials agreed to slow the pace of reducing bond holdings on their balance sheet, leading to a slight easing of monetary policy. The Federal Open Market Committee kept…